Search Result

Results for "

active doxorubicin

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (2) Aminopeptidase (1) Angiotensin-converting Enzyme (ACE) (1) Apoptosis (16) Autophagy (11) Bacterial (9) DNA-PK (2) Endogenous Metabolite (4) FAK (1) FAP (1) Ferroptosis (2) Isotope-Labeled Compounds (6) Keap1-Nrf2 (2) Lipoxygenase (1) Organoid (2) Peptide-Drug Conjugates (PDCs) (1) Proton Pump (10) Reactive Oxygen Species (ROS) (4) Reference Standards (3) ROCK (3) ROS Kinase (2) Sirtuin (1)
By Research Areas:	Cancer (21) Cardiovascular Disease (4) Endocrinology (2) Inflammation/Immunology (12) Metabolic Disease (2)

By Targets:

Adrenergic Receptor (2)

Aminopeptidase (1)

Angiotensin-converting Enzyme (ACE) (1)

Apoptosis (16)

Autophagy (11)

Bacterial (9)

DNA-PK (2)

Endogenous Metabolite (4)

FAK (1)

FAP (1)

Ferroptosis (2)

Isotope-Labeled Compounds (6)

Keap1-Nrf2 (2)

Lipoxygenase (1)

Organoid (2)

Peptide-Drug Conjugates (PDCs) (1)

Proton Pump (10)

Reactive Oxygen Species (ROS) (4)

Reference Standards (3)

ROCK (3)

ROS Kinase (2)

Sirtuin (1)

By Research Areas:

Cancer (21)

Cardiovascular Disease (4)

Endocrinology (2)

Inflammation/Immunology (12)

Metabolic Disease (2)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-117071

Dabuzalgron Ro 115-1240	Adrenergic Receptor Apoptosis	Cardiovascular Disease Endocrinology
Dabuzalgron (Ro 115-1240) is an orally active and selective α-1A adrenergic receptor agonist for the treatment of urinary incontinence. Dabuzalgron protects against Doxorubicin-induced cardiotoxicity by preserving mitochondrial function .

HY-B0655

Zofenopril calcium SQ26991	Angiotensin-converting Enzyme (ACE) Reactive Oxygen Species (ROS)	Cardiovascular Disease
Zofenopril Calcium (SQ26991) is an orally active angiotensin-converting enzyme (ACE) inhibitor with antioxidant activity and cardioprotective effects. Zofenopril Calcium reduces ROS production and GSH consumption and helps inhibit foam cell formation, thus slowing the progression of atherosclerosis. Zofenopril Calcium prevents cardiac damage caused by chronic Doxorubicin (HY-15142A).

HY-146565

DNA-PK-IN-8	DNA-PK	Cancer
DNA-PK-IN-8 is a highly potent, selective and orally active DNA-dependent protein kinase (DNA-PK) inhibitor with an IC₅₀ value of 0.8 nM. DNA-PK-IN-8 exhibits synergistic antiproliferative activity against a series of cancer cell lines and significantly suppresses HL-60 tumor growth, when using in combination with Doxorubicin .

HY-17507

Pantoprazole 3 Publications Verification BY1023; SKF96022	Proton Pump Autophagy Apoptosis Bacterial	Inflammation/Immunology Cancer
Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-17507B

Pantoprazole sodium hydrate 3 Publications Verification BY1023 sodium hydrate; SKF96022 sodium hydrate	Proton Pump Autophagy Apoptosis Bacterial	Inflammation/Immunology Cancer
Pantoprazole sodium hydrate (BY10232 sodium hydrate) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole sodium hydrate, a substituted benzimidazole, is a potent H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole sodium hydrate improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium hydrate significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-177083

Faridoxorubicin AVA-6000	FAP	Cancer
Faridoxorubicin (AVA-6000) is a prodrug targeting fibroblast activation protein α (FAPα). Faridoxorubicin releases active doxorubicin through FAPα-mediated cleavage, enhancing intratumoral drug exposure and reducing cardiac toxicity. Faridoxorubicin is promising for research of solid tumors (e.g., colorectal cancer liver metastasis) .

HY-145427

NU5455	DNA-PK	Cancer
NU5455 is a potent, selective, and orally active inhibitor of DNA-PKcs. NU5455 administration increases both the efficacy and the toxicity of a parenterally administered topoisomerase inhibitor. NU5455 enhances the activity of Doxorubicin released locally in liver tumor xenografts without inducing any adverse effect .

HY-129410

ADR-925	Endogenous Metabolite	Others
ADR-925 is an active chelated iron metabolite with the ability to protect neonatal rat cardiomyocytes from doxorubicin (HY-15142A)-induced damage .

HY-P10759

DTS-201 sodium	Peptide-Drug Conjugates (PDCs) Aminopeptidase	Cancer
DTS-201 sodium (CPI-0004Na) is a peptidic prodrug of Doxorubicin (HY-15142A). DTS-201, comprising the tetrapeptide portion, is cleaved by endopeptidases in the tumor environment to produce metabolites that subsequently enter the cell and are converted to active Doxorubicin. DTS-201 shows antitumoral efficacy in tumor xenograft models of prostate, breast, and lung cancer .

HY-117071A

Dabuzalgron hydrochloride Ro 115-1240 hydrochloride	Adrenergic Receptor Apoptosis	Cardiovascular Disease Endocrinology
Dabuzalgron (Ro 115-1240) hydrochloride is an orally active and selective α-1A adrenergic receptor agonist for the treatment of urinary incontinence. Dabuzalgron hydrochloride protects against Doxorubicin-induced cardiotoxicity by preserving mitochondrial function .

HY-17507A

Pantoprazole sodium 3 Publications Verification BY1023 sodium; SKF96022 sodium	Proton Pump Autophagy Apoptosis Bacterial	Inflammation/Immunology Cancer
Pantoprazole sodium (BY10232 sodium) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole sodium, a substituted benzimidazole, is a potent H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole sodium improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-17507S

Pantoprazole-d6 BY1023-d₆; SKF96022-d₆	Isotope-Labeled Compounds Proton Pump Autophagy Apoptosis	Inflammation/Immunology Cancer
Pantoprazole-d₆ is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-17507S1

Pantoprazole-d3 BY1023-d₃; SKF96022-d₃	Isotope-Labeled Compounds Proton Pump Autophagy Apoptosis	Inflammation/Immunology Cancer
Pantoprazole-d₃ is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-40161

Indole-3-carboxylic acid 1 Publications Verification	Endogenous Metabolite Bacterial	Metabolic Disease Cancer
Indole-3-carboxylic acid is an orally active urinary indolic tryptophan metabolite. Indole-3-carboxylic acid is a mediator of priming against *Plectosphaerella cucumerina. Indole-3-carboxylic acid enhances the anti-colorectal cancer potency of Doxorubicin* (HY-15142A) by inducing cell senescence. Indole-3-carboxylic acid can be used in liver disease research .

HY-173572

SKLB-11A	Sirtuin Autophagy	Cardiovascular Disease
SKLB-11A is a selective, orally active and allosteric SIRT3 (sirtuin 3) agonist with a K_d value of 4.7 μM. SKLB-11A is highly selective for other members of the SIRT family. SKLB-11A activates autophagy-related signaling pathways, prevents mitochondrial dysfunction, improves cardiac function in Doxorubicin (HY-15142A)-induced cardiotoxicity and myocardial ischemia/reperfusion models .

HY-17507R

Pantoprazole (Standard) BY1023 (Standard); SKF96022 (Standard)	Reference Standards Proton Pump Autophagy Apoptosis Bacterial	Inflammation/Immunology Cancer
Pantoprazole (Standard) is the analytical standard of Pantoprazole. This product is intended for research and analytical applications. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-17507AR

Pantoprazole sodium (Standard) BY1023 sodium (Standard); SKF96022 sodium (Standard)	Reference Standards Proton Pump Autophagy Apoptosis Bacterial	Inflammation/Immunology Cancer
Pantoprazole (sodium) (Standard) is the analytical standard of Pantoprazole (sodium). This product is intended for research and analytical applications. Pantoprazole sodium (BY10232 sodium) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole sodium, a substituted benzimidazole, is a potent H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole sodium improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-17507BR

Pantoprazole sodium hydrate (Standard) BY1023 sodium hydrate (Standard); SKF96022 sodium hydrate (Standard)	Reference Standards Proton Pump Autophagy Apoptosis Bacterial	Inflammation/Immunology Cancer
Pantoprazole (sodium hydrate) (Standard) is the analytical standard of Pantoprazole (sodium hydrate). This product is intended for research and analytical applications. Pantoprazole sodium hydrate (BY10232 sodium hydrate) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole sodium hydrate, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole sodium hydrate improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium hydrate significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-17507S2

Pantoprazole-d8 BY1023-d₈; SKF96022-d₈	Isotope-Labeled Compounds Bacterial Autophagy Apoptosis Proton Pump	Inflammation/Immunology Cancer
Pantoprazole-d₈ (BY1023-d₈) is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-W739793

Pantoprazole-d8 sodium BY1023-d₈ sodium; SKF96022-d₈ sodium	Isotope-Labeled Compounds Proton Pump Autophagy Apoptosis Bacterial	Inflammation/Immunology Cancer
Pantoprazole-d₈ (BY1023-d₈) sodium is a deuterium labeled Pantoprazole (HY-17507). Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-17507S4

Pantoprazole-d4 BY1023-d₄; SKF96022-d₄	Isotope-Labeled Compounds	Inflammation/Immunology Cancer
Pantoprazole-d₄ (BY1023-d₄) is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-10071

Y-27632 Maximum Cited Publications 376 Publications Verification	Organoid ROCK Apoptosis	Cancer
Y-27632 is an orally active, ATP-competitive inhibitor of ROCK-I and ROCK-II, with K_is of 220 and 300 nM, respectively. Y-27632 attenuates Doxorubicin-induced apoptosis of human cardiac stem cells. Y-27632 also suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells. Y-27632 primes human induced pluripotent stem cells (hIPSCs) to selectively differentiate towards mesendodermal lineage via epithelial-mesenchymal transition-like modulation .

HY-10071A

Y-27632 hydrochloride hydrate	Organoid ROCK Apoptosis	Cancer
Y-27632 hydrochloride hydrate is an orally active, ATP-competitive inhibitor of ROCK-I and ROCK-II, with K_is of 220 and 300 nM, respectively. Y-27632 hydrochloride hydrate attenuates Doxorubicin-induced apoptosis of human cardiac stem cells. Y-27632 hydrochloride hydrate also suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells. Y-27632 hydrochloride hydrate primes human induced pluripotent stem cells (hIPSCs) to selectively differentiate towards mesendodermal lineage via epithelial-mesenchymal transition-like modulation .

HY-N0394

L-Cystine 2 Publications Verification	Endogenous Metabolite Ferroptosis ROS Kinase Keap1-Nrf2 Reactive Oxygen Species (ROS)	Metabolic Disease Inflammation/Immunology Cancer
L-Cystine is an orally active extracellular form of L-Cysteine (HY-Y0337), occurring in proteins of plants and animals. L-Cystine elevates Nrf2 protein expression and activates Nrf2 transcription factor. L-cystine reduces ROS generation and protects against oxidant- or Doxorubicin (HY-15142A)-induced apoptosis. L-Cystine combined with L-theanine (HY-15121) enhances the production of antigen-specific IgG by increasing glutathione (GSH) levels and T helper 2 (Th2) mediated responses in mice. L-Cystine is promising for research of cystinuria and kidney stones

HY-W700452

Y-27632-d4 hydrochloride hydrate	Isotope-Labeled Compounds Apoptosis ROCK	Cancer
Y-27632-d₄ hydrochloride hydrate is the deuterium labeled Y-27632 hydrochloride hydrate (HY-10071A). Y-27632 hydrochloride hydrate is an orally active, ATP-competitive inhibitor of ROCK-I and ROCK-II, with Kis of 220 and 300 nM, respectively. Y-27632 hydrochloride hydrate attenuates Doxorubicin-induced apoptosis of human cardiac stem cells. Y-27632 hydrochloride hydrate also suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells. Y-27632 hydrochloride hydrate primes human induced pluripotent stem cells (hIPSCs) to selectively differentiate towards mesendodermal lineage via epithelial-mesenchymal transition-like modulation .

HY-W009356

L-Cystine hydrochloride	Endogenous Metabolite Ferroptosis ROS Kinase Keap1-Nrf2 Reactive Oxygen Species (ROS)	Others
L-Cystine hydrochloride is an orally active extracellular form of L-Cysteine (HY-Y0337), occurring in proteins of plants and animals. L-Cystine hydrochloride elevates Nrf2 protein expression and activates Nrf2 transcription factor. L-Cystine hydrochloride reduces ROS generation and protects against oxidant- or Doxorubicin (HY-15142A)-induced apoptosis. L-Cystine hydrochloride combined with L-theanine (HY-15121) enhances the production of antigen-specific IgG by increasing glutathione (GSH) levels and T helper 2 (Th2) mediated responses in mice. L-Cystine hydrochloride is promising for research of cystinuria and kidney stones

HY-171955

LXG6403	Lipoxygenase Apoptosis Reactive Oxygen Species (ROS) FAK	Cancer
LXG6403 is an orally active and irreversible LOX inhibitor (IC₅₀ = 1.3 μM). LXG6403 is ~3.5-fold more specific for LOX than LOXL2 and does not inhibit LOXL1. LXG6403 inhibits FAK signaling and induces ROS generation and DNA damage, leading to G1 arrest and apoptosis in chemoresistant triple-negative breast cancer (TNBC) cell lines. LXG6403 alters the extracellular matrix (ECM) and collagen structure, reducing collagen cross-linking and deposition, thereby increasing drug penetration and reducing tumor stiffness. LXG6403 overcomes Doxorubicin resistance in chemoresistant TNBC PDX in vivo and can be used to study high-stiffness resistant tumors .

Cat. No.	Product Name	Target	Research Area

HY-W009356

L-Cystine hydrochloride	Endogenous Metabolite Ferroptosis ROS Kinase Keap1-Nrf2 Reactive Oxygen Species (ROS)	Others
L-Cystine hydrochloride is an orally active extracellular form of L-Cysteine (HY-Y0337), occurring in proteins of plants and animals. L-Cystine hydrochloride elevates Nrf2 protein expression and activates Nrf2 transcription factor. L-Cystine hydrochloride reduces ROS generation and protects against oxidant- or Doxorubicin (HY-15142A)-induced apoptosis. L-Cystine hydrochloride combined with L-theanine (HY-15121) enhances the production of antigen-specific IgG by increasing glutathione (GSH) levels and T helper 2 (Th2) mediated responses in mice. L-Cystine hydrochloride is promising for research of cystinuria and kidney stones

HY-P10759

DTS-201 sodium	Peptide-Drug Conjugates (PDCs) Aminopeptidase	Cancer
DTS-201 sodium (CPI-0004Na) is a peptidic prodrug of Doxorubicin (HY-15142A). DTS-201, comprising the tetrapeptide portion, is cleaved by endopeptidases in the tumor environment to produce metabolites that subsequently enter the cell and are converted to active Doxorubicin. DTS-201 shows antitumoral efficacy in tumor xenograft models of prostate, breast, and lung cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-40161

Indole-3-carboxylic acid 1 Publications Verification	Alkaloids Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Indole Alkaloids	Endogenous Metabolite Bacterial
Indole-3-carboxylic acid is an orally active urinary indolic tryptophan metabolite. Indole-3-carboxylic acid is a mediator of priming against *Plectosphaerella cucumerina. Indole-3-carboxylic acid enhances the anti-colorectal cancer potency of Doxorubicin* (HY-15142A) by inducing cell senescence. Indole-3-carboxylic acid can be used in liver disease research .

HY-N0394

L-Cystine 2 Publications Verification	Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Source classification Other Diseases Amino acids Endogenous metabolite Disease Research Fields	Endogenous Metabolite Ferroptosis ROS Kinase Keap1-Nrf2 Reactive Oxygen Species (ROS)
L-Cystine is an orally active extracellular form of L-Cysteine (HY-Y0337), occurring in proteins of plants and animals. L-Cystine elevates Nrf2 protein expression and activates Nrf2 transcription factor. L-cystine reduces ROS generation and protects against oxidant- or Doxorubicin (HY-15142A)-induced apoptosis. L-Cystine combined with L-theanine (HY-15121) enhances the production of antigen-specific IgG by increasing glutathione (GSH) levels and T helper 2 (Th2) mediated responses in mice. L-Cystine is promising for research of cystinuria and kidney stones

Cat. No.	Product Name	Chemical Structure

HY-W739793

Pantoprazole-d8 sodium
Pantoprazole-d₈ (BY1023-d₈) sodium is a deuterium labeled Pantoprazole (HY-17507). Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

Pantoprazole-d8 sodium

Pantoprazole-d₈ (BY1023-d₈) sodium is a deuterium labeled Pantoprazole (HY-17507). Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-17507S

Pantoprazole-d6
Pantoprazole-d₆ is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

Pantoprazole-d6

Pantoprazole-d₆ is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-17507S1

Pantoprazole-d3
Pantoprazole-d₃ is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

Pantoprazole-d3

Pantoprazole-d₃ is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-17507S2

Pantoprazole-d8
Pantoprazole-d₈ (BY1023-d₈) is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

Pantoprazole-d8

Pantoprazole-d₈ (BY1023-d₈) is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-17507S4

Pantoprazole-d4
Pantoprazole-d₄ (BY1023-d₄) is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

Pantoprazole-d4

Pantoprazole-d₄ (BY1023-d₄) is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-W700452

Y-27632-d4 hydrochloride hydrate
Y-27632-d₄ hydrochloride hydrate is the deuterium labeled Y-27632 hydrochloride hydrate (HY-10071A). Y-27632 hydrochloride hydrate is an orally active, ATP-competitive inhibitor of ROCK-I and ROCK-II, with Kis of 220 and 300 nM, respectively. Y-27632 hydrochloride hydrate attenuates Doxorubicin-induced apoptosis of human cardiac stem cells. Y-27632 hydrochloride hydrate also suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells. Y-27632 hydrochloride hydrate primes human induced pluripotent stem cells (hIPSCs) to selectively differentiate towards mesendodermal lineage via epithelial-mesenchymal transition-like modulation .

Y-27632-d4 hydrochloride hydrate

Y-27632-d₄ hydrochloride hydrate is the deuterium labeled Y-27632 hydrochloride hydrate (HY-10071A). Y-27632 hydrochloride hydrate is an orally active, ATP-competitive inhibitor of ROCK-I and ROCK-II, with Kis of 220 and 300 nM, respectively. Y-27632 hydrochloride hydrate attenuates Doxorubicin-induced apoptosis of human cardiac stem cells. Y-27632 hydrochloride hydrate also suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells. Y-27632 hydrochloride hydrate primes human induced pluripotent stem cells (hIPSCs) to selectively differentiate towards mesendodermal lineage via epithelial-mesenchymal transition-like modulation .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks